Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Europe Our alerts service is now closed until 7th January ...
  • Czech Republic Law reform to decriminalise adult use of cannabis passes first reading ...
  • France Concern about disruption in medical cannabis patients’ treatment ...
  • United States Resolution introduced that extends 2018 Farm Bill another year ...
  • Denmark Danish Medicines Agency approves medical cannabis oil product ...
  • Ohio - United States Bill to ban sale of intoxicating hemp products unlikely to move forward ...
  • Europe European Council adopts regulation to reduce and recycle packaging ...
  • Germany Two Berlin districts to start recreational cannabis sales ...
  • Nebraska - United States Two cannabis measures signed into law ...
  • Brazil AGU requests extension on deadline for cannabis regulations ...
  • Switzerland Bern recreational cannabis project extended ...
  • Japan Law in force today criminalises recreational and legalises medical cannabis ...
View all
News analysis

Cannabis in the UK now medically legal – up to a point

Written by || 1st November 2018 || News analysis | Regulation and legislation | GeographiesEurope United Kingdom

Medical cannabis products are legal in the UK from today – in very limited circumstances. This could include products without marketing authorisation, if approved by a registered specialist in certain conditions.

A change in the law brought about in a few short months enables cannabis-based products for medicinal use in humans to be prescribed as a Schedule 2 drug – essentially drugs that can be legally prescribed but carry higher risks for potential abuse.

This could be a special medicinal product for use at the direction of a doctor on the General Medical Council’s specialist register; an investigational medicinal product without marketing authorisation for use in a clinical trial; or a medicinal product with a marketing authorisation.

Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Freddie Dawson

Senior news editor
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the CannIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.